Skip to main
PRCT
PRCT logo

PRCT Stock Forecast & Price Target

PRCT Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PROCEPT BioRobotics Corp has demonstrated consistent growth in utilization, with an average increase of approximately 6.1% in hand pieces per system over the past six quarters, indicating strengthening demand for its products. The company has strategically decided to limit the growth of operating expenses to half of its top-line growth rate, which reflects a dedication to enhancing profitability as it continues to scale operations. Moreover, management's positive outlook is supported by strong performance in capital system placements, with 58 new systems installed in the latest quarter, surpassing previous guidance and suggesting robust market acceptance despite external economic challenges.

Bears say

PROCEPT BioRobotics Corp has experienced a significant decline in its stock price, down approximately 54% year-to-date, despite attempts to surpass its own financial guidance. The company is facing several fundamental challenges, including a potential decline in demand for capital equipment, decreased usage of handpieces by customers, and intensifying competitive pressures, alongside uncertainties related to reimbursement for its Aquablation therapy. Additionally, the consensus forecast for sales in 2026 is anticipated to decrease, reflecting investor concerns regarding utilization rates and inventory levels, further contributing to the negative outlook.

PRCT has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PROCEPT BioRobotics Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PROCEPT BioRobotics Corp (PRCT) Forecast

Analysts have given PRCT a Buy based on their latest research and market trends.

According to 7 analysts, PRCT has a Buy consensus rating as of Dec 6, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PROCEPT BioRobotics Corp (PRCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.